Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.61 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.56 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.56 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PRCP | P42785 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22160536 | 1.00 | NAAA (0.61) | NAAAGNAI3GNAO1GNAI1GAA | |
| SCHEMBL22160579 | 1.00 | NAAA (0.61) | NAAAGNAI3GNAO1GNAI1GAA | |
| SCHEMBL22160533 | 1.00 | NAAA (0.61) | NAAAGNAI3GNAO1GNAI1GAA | |
| SCHEMBL22160655 | 1.00 | NAAA (0.61) | NAAAGNAI3GNAO1GNAI1GAA | |
| SCHEMBL22160679 | 1.00 | NAAA (0.61) | NAAAGNAI3GNAO1GNAI1GAA | |
| SCHEMBL22160572 | 1.00 | NAAA (0.61) | NAAAGNAI3GNAO1GNAI1GAA | |
| SCHEMBL22160649 | 1.00 | NAAA (0.61) | NAAAGNAI3GNAO1GNAI1GAA | |
| SCHEMBL22160665 | 1.00 | NAAA (0.61) | NAAAGNAI3GNAO1GNAI1GAA | |
| SCHEMBL22160570 | 1.00 | NAAA (0.61) | NAAAGNAI3GNAO1GNAI1GAA | |
| SCHEMBL22160648 | 1.00 | NAAA (0.61) | NAAAGNAI3GNAO1GNAI1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040959-B2 | Diprovocims: a new and potent class of TLR agonists | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3445758-B1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | SCRIPPS RESEARCH INST (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | THE SCRIPPS RESEARCH INSTITUTE | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | TLR1, TLR4, TLR2 | NAAA 3597/4885GNAI3 2266/4885GNAO1 1783/4885 |
| US-11040959-B2 | Diprovocims: a new and potent class of TLR agonists | TLR1, TLR4, TLR2 | NAAA 3546/4885GNAI3 2152/4885GNAO1 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.